167 related articles for article (PubMed ID: 31702003)
1. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.
Slater TA; Drozd M; Palin V; Bowles C; Waduud MA; Khatib R; Ajjan RA; Wheatcroft SB
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):194-196. PubMed ID: 31702003
[No Abstract] [Full Text] [Related]
2. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
Nassif ME; Kosiborod M
Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
[No Abstract] [Full Text] [Related]
3. The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.
Fatima S; Jameel A; Ayesha F; Menzies DJ
Clin Cardiol; 2017 Nov; 40(11):970-973. PubMed ID: 28841228
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
Shehadeh N; Raz I; Nakhleh A
Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
[No Abstract] [Full Text] [Related]
5. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.
Gurgle HE; White K; McAdam-Marx C
Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752
[TBL] [Abstract][Full Text] [Related]
6. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
[TBL] [Abstract][Full Text] [Related]
7. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
8. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.
Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD;
Eur J Prev Cardiol; 2015 Jun; 22(6):753-61. PubMed ID: 24691153
[TBL] [Abstract][Full Text] [Related]
9. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Mosenzon O; Del Prato S; Schechter M; Leiter LA; Ceriello A; DeFronzo RA; Raz I
Cardiovasc Diabetol; 2021 Apr; 20(1):92. PubMed ID: 33910583
[TBL] [Abstract][Full Text] [Related]
10. Regular mailing of personalized feedback reports improves glycemic control in diabetes: A randomized controlled trial.
Yin J; Luk A; Wong R; Chung H; Kong A; Ozaki R; Ma R; Chow CC; So W; Chan J
J Diabetes; 2017 May; 9(5):536-538. PubMed ID: 28083979
[No Abstract] [Full Text] [Related]
11. Emerging glucose-lowering therapies: a guide for cardiologists.
Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
[TBL] [Abstract][Full Text] [Related]
13. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
[TBL] [Abstract][Full Text] [Related]
14. Impact of Incretin-Based Therapies on Adipokines and Adiponectin.
Yaribeygi H; Maleki M; Atkin SL; Jamialahmadi T; Sahebkar A
J Diabetes Res; 2021; 2021():3331865. PubMed ID: 34660808
[TBL] [Abstract][Full Text] [Related]
15. Diabetes News.
Regier EE; Gao HX; Close KL
J Diabetes; 2015 Nov; 7(6):749-53. PubMed ID: 26223410
[No Abstract] [Full Text] [Related]
16. Improved outcomes from diabetes monitoring: the benefits of better adherence, therapy adjustments, patient education, and telemedicine support.
Klonoff DC
J Diabetes Sci Technol; 2012 May; 6(3):486-90. PubMed ID: 22768877
[No Abstract] [Full Text] [Related]
17. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
18. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
Pagidipati NJ; Lopes RD
J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
[No Abstract] [Full Text] [Related]
19. Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent therapy choices: a comparison across health states.
McAlister FA; Lethebe BC; Lambe C; Williamson T; Lowerison M
Cardiovasc Diabetol; 2018 Feb; 17(1):27. PubMed ID: 29433515
[TBL] [Abstract][Full Text] [Related]
20. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
